NorthWest Biotherapeutics Inc (NWBO)

[biosectinvestor]

They had submitted a new SAP, and they knew what they were going to submit, as the approached the task quite a bit ahead of the data lock. They knew they were relying on OS, not PFS, and they knew from the blinded interim where they were likely going to go with that OS measure.

The manipulation of data comes when companies and researchers look for fake measures of OS, that are not OS to justify approval without OS data. You can’t fake OS. People are alive or they are not. People try to project OS with PFS, but pseudoresponse has been a bigger issue than any will admit. PFS is not a reliable predictor of OS but sometimes it will satisfy other measures of benefit even if their is no improvement of OS.

This treatment has few to no side-effects, can also treat recurrence, and substantially and significantly increases OS, without necessarily becoming a forever obligation to pay through the nose to be forever basically recurrent. This treatment has the potential to cure, and also in combination with other treatments to lead to a cure for more patients and also to be a treatment for many kinds of cancers, creating potentially immense industrial scalability, which should substantially bring down the cost to everyone and make oncology treatments for less difficult for many kinds of patients suffering from cancers and tumors.